ME NewsWire/ Business Wire

WALTHAM, Mass. - Wednesday, May 14th 2014

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has partnered with the International AIDS Society (IAS) to provide UpToDate® to society members. The partnership was facilitated by the company’s medical journal publishing business, Lippincott Williams & Wilkins (LWW). LWW is the publisher of AIDS, among other leading medical, nursing and allied health society journals. More than 850,000 clinicians in 164 countries currently rely on UpToDate to make the right point of care decisions.

“Working closely with UpToDate enables us to provide our members with access to trusted clinical decision support that will help them improve the care they provide. UpToDate has served as a critical resource for developing an evidence-based response to HIV and AIDS. We are committed to supporting our members with ... Read more »

NEW YORK - Thursday, May 15th 2014 [ME NewsWire]

(BUSINESS WIRE) 21st Century Fox confirms its intent to form a joint venture with funds managed by affiliates of Apollo Global Management comprised of Endemol, Shine Group and CORE Media Group. The parties have entered into a preliminary agreement, subject to a number of conditions, which calls for 21st Century Fox and funds managed by affiliates of Apollo to jointly own and manage the new joint venture.

There can be no assurance that the proposed transaction will be completed.

About 21st Century Fox

21st Century Fox is the world's premier portfolio of cable, broadcast, film, pay TV and satellite assets spanning six continents across the globe. Reaching nearly 1.5 billion subscribers in more than 100 local languages every day, 21st Century Fox is home to a global portfolio of cable and broadcasting networks and properties, including FOX, FX, FXX, FXM, FS1, Fox News Channel, Fox Business Network, Fox ... Read more »

ME Newswire / Businesswire

FRAMINGHAM, Mass. - Thursday, May 15th 2014

LFB SA, through its U.S. subsidiary, announced today that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients with congenital hemophilia A or B with inhibitors.

This Phase 3 clinical trial is a global open-label, multicenter study designed to evaluate the efficacy, safety and pharmacokinetics of LR769 in adolescent and adult hemophilia A and B patients with inhibitors. The study will evaluate two dosing regimens for the treatment of bleeding episodes and should be completed in 2015. More details can be found on www.clinicaltrials.gov, study identifier NCT02020369.

“The start of patient treatment is an important milestone in the development of LR769 for hemophilia A and B patients with inhibitors to Factor VIII or IX. LFB is committed to working with the hemophilia community to find new tr ... Read more »

ME NewsWire/ Business Wire

INGELHEIM, Germany - Thursday, May 15th 2014

    Overall survival results from a post-hoc analysis combining the data of two Phase III studies (LUX-Lung 3 and LUX-Lung 6) demonstrate that first-line afatinib treatment reduced the risk of death by 19% for patients with lung cancer with common types of EGFR mutations.1
    Patients lived a median of three months longer if they started treatment with afatinib rather than chemotherapy.1
    A separate Phase III study (LUX-Lung 5) in patients whose lung cancer progressed after several treatments, showed the advantage of continuing afatinib with chemotherapy after the tumours started to grow under afatinib alone.2

For Ex-US and Ex-UK Media Only

Boehringer Ingelheim today announced new overall survival results from a post-hoc analysis combining the data of two Phase III trials (LUX-Lung 3 and LUX-Lung 6). The analysis showed ... Read more »